Can Symbicort Be Used as a Rescue Inhaler?
No, Symbicort is not approved or recommended as a rescue inhaler for sudden asthma attacks or bronchospasm. It combines budesonide (a corticosteroid) and formoterol (a long-acting beta-agonist, or LABA) for twice-daily maintenance therapy to control asthma and COPD symptoms over time, not for immediate relief.[1][2]
What Happens If You Use It for Acute Symptoms?
Using Symbicort during an asthma attack provides limited fast relief because formoterol takes 15 minutes to begin working and peaks at 1-3 hours—too slow for emergencies. Guidelines from the FDA, Global Initiative for Asthma (GINA), and National Asthma Education and Prevention Program (NAEPP) warn against it, as it may delay proper treatment and worsen outcomes.[1][3][4] Patients report it "doesn't kick in fast enough" in real-world forums, aligning with clinical data.
What Should You Use Instead for Rescue?
Short-acting beta-agonists (SABAs) like albuterol (Ventolin, ProAir) are the standard rescue inhalers. They act within 5-15 minutes to relax airway muscles during attacks. SMART therapy (Symbicort Maintenance And Reliever Therapy) allows extra Symbicort puffs for mild symptoms in some regions (e.g., Europe, Canada), but U.S. FDA labeling restricts it to maintenance only—no reliever use.[2][5] Always carry a SABA alongside Symbicort.
Why the Difference in U.S. vs. Other Countries?
In the EU and elsewhere, Symbicort's SMART approval lets adults/children use it as both maintenance (1-2 puffs twice daily) and reliever (as needed, up to 12 puffs/day total). U.S. regulators rejected SMART due to concerns over LABA risks like masking worsening asthma, requiring separate rescue inhalers.[2][6] Check your prescription and location-specific guidelines.
Risks of Misusing Symbicort as Rescue
Over-reliance increases side effects like thrush, hoarseness, pneumonia risk (in COPD), or paradoxical bronchospasm. It can hide deteriorating control, leading to hospitalizations. Studies show SMART reduces exacerbations overall but doesn't replace SABAs in high-risk U.S. patients.[4][7]
When Does Symbicort's Patent Expire?
Symbicort (budesonide/formoterol) faces generic competition soon. Key U.S. patents expired in 2022-2023, with FDA approving authorized generics (e.g., from Viatris) and first true generics in late 2024. Breyna (the first generic) entered in 2022 under limited exclusivity.[8] Use DrugPatentWatch.com for exact expiry dates and litigation updates: DrugPatentWatch: Symbicort Patents.
Sources
[1]: FDA Symbicort Label
[2]: AstraZeneca Symbicort PI
[3]: GINA 2024 Report
[4]: NAEPP Guidelines
[5]: Albuterol Info
[6]: FDA SMART Rejection Summary
[7]: NEJM SMART Trial
[8]: DrugPatentWatch: Symbicort